Clinical Trials Logo

Hyperaldosteronism clinical trials

View clinical trials related to Hyperaldosteronism.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05686993 Active, not recruiting - Clinical trials for Primary Aldosteronism

Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism

Start date: May 5, 2023
Phase: N/A
Study type: Interventional

The goal of this pilot, open-label prospective study is to evaluate if the effect of calcium channel blockade on plasma aldosterone levels in people with primary aldosteronism (PA) is due primarily to Cav1.3 blockade. This will be tested by treating participants who have PA with both cinnarizine (Cav1.3 blocker) and nifedipine (Cav1.2 blocker) and evaluating effect on aldosterone levels and blood pressure over a two week course of treatment.

NCT ID: NCT05446779 Active, not recruiting - Pheochromocytoma Clinical Trials

Postmortem Evaluation of Adrenal and Other Endocrine Tumors in Patients With Sudden Death

SuddenDeath
Start date: February 3, 2022
Phase:
Study type: Observational

Sudden Cardiac Death is a leading cause of mortality and remains a major public health burden worldwide. Cardiac arrest due to coronary heart disease explains a large proportion of the cases, but if autopsy is not performed the exact underlying cause remains obscure in many adults who face sudden death outside heath care organizations. The investigators aim to find proof that primary aldosteronism is a risk factor for sudden death and to characterize the prevalence of adrenal pathology in sudden death of undetermined cause in a case-control study. In addition, the study aims to characterize the prevalence of other adrenal pathology i.e. silent adenomas, cortisol-producing adenomas and pheochromocytomas in sudden death. The investigators also seek evidence that other endocrine hormone overproduction-causing diseases are more prevalent in persons with sudden death compared with those experiencing traumatic or suicidal death sudden death.

NCT ID: NCT04605549 Active, not recruiting - Clinical trials for Primary Aldosteronism

A Study of CIN-107 in Adults With Primary Aldosteronism

Start date: March 8, 2021
Phase: Phase 2
Study type: Interventional

This is a multicenter, open-label study in adult patients with PA to evaluate the effectiveness and safety of CIN-107 after up to 12 weeks of treatment (Part 1), and then for eligible, consenting patients follow patients in Part 2 for up to 74 weeks for evidence of long-term safety and tolerability.

NCT ID: NCT02030587 Active, not recruiting - Hyperaldosteronism Clinical Trials

Laparoscopic Adrenalectomy Versus Radiofrequency Ablation

LARFA
Start date: January 2013
Phase: N/A
Study type: Interventional

This is a prospective randomized controlled study comparing laparoscopic adrenalectomy (LA) versus image-guided percutaneous radiofrequency ablation (RFA) in treating aldosterone-producing adenoma. The objectives of this study are to 1. compare the short-term outcomes of LA and RFA in treating aldosterone-producing adenoma. 2. compare the treatment success rates of LA and RFA during follow-up for primary aldosteronism.